Industry progress report on neuro-oncology: Biotech update 2013

Journal of Neuro-Oncology

Volumn 115, Issue 2, 2013, Pages 311-316

  Ottenhausen, Malte ^a   Bodhinayake, Imithri ^a   Banu, Matei ^a   Kesavabhotla, Kartik ^a   Ray, Ashley ^a   Boockvar, John A ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Biotech; Clinical trials; Emerging therapy; GBM; Glioma

Indexed keywords

AMINOLEVULINIC ACID; ANTIBODY CONJUGATE; BEVACIZUMAB; BRENTUXIMAB VEDOTIN; CANCER ANTIBODY; CANCER VACCINE; CHIMERIC PROTEIN; DCVAX DIRECT; DCVAX L; DENDRITIC CELL VACCINE; EPHRIN B2; EPHRIN RECEPTOR B4; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 96 PEPTIDE COMPLEX VACCINE; ICT 107; ICT 121; PROPHAGE SERIES 100; PROPHAGE SERIES 200; RECOMBINANT HUMAN SERUM ALBUMIN; TEMOZOLOMIDE; TUMOR ANTIGEN; UNCLASSIFIED DRUG; VEDOTIN; VOCIMAGENE AMIRETROREPVEC;

ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOMEDICINE; BIOTECHNOLOGY; BRAIN METASTASIS; BRAIN TUMOR; CANCER IMMUNIZATION; CANCER SURVIVAL; CANCER THERAPY; CYTOLOGY; CYTOPLASM VESICLE; DENDRITIC CELL; DIAGNOSTIC VALUE; DRUG APPROVAL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG INDUSTRY; DRUG SAFETY; EXOSOME; FINANCIAL MANAGEMENT; FLUORESCENCE ANALYSIS; GLIOBLASTOMA; GLIOMA; HEALTH CARE DELIVERY; HEALTH CARE INDUSTRY; HODGKIN DISEASE; HUMAN; IMMUNE RESPONSE; LARGE CELL LYMPHOMA; LEADERSHIP; LUNG SMALL CELL CANCER; MASS COMMUNICATION; MEDICAL RESEARCH; MEDICAL SOCIETY; MESOTHELIOMA; MOLECULAR DIAGNOSIS; MOLECULARLY TARGETED THERAPY; NEUROONCOLOGY; NEUROSURGEON; NON PROFIT ORGANIZATION; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOLOGIST; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROFESSIONAL PRACTICE; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCIENTIST; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; ULTRASOUND; ULTRASOUND SCANNER;

BIOTECHNOLOGY; BRAIN NEOPLASMS; CANCER VACCINES; DRUG INDUSTRY; HUMANS; MOLECULAR TARGETED THERAPY; PHARMACEUTICAL PREPARATIONS; RESEARCH REPORT;

EID: 84886586830     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-013-1222-3     Document Type: Article

References (40)

1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO, European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups, National Cancer Institute of Canada Clinical Trials Group (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996. doi: 10.1056/NEJMoa043330
2. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M, Cloughesy T (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J clin oncol 27:4733-4740. doi: 10.1200/JCO.2008.19.8721
3. Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, Garren N, Mackey M, Butman JA, Camphausen K, Park J, Albert PS, Fine HA (2009) Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J clin oncol 27:740-745. doi: 10.1200/JCO.2008.16.3055
4. Health NIo (2013) NIH Fiscal Policy for Grant Awards - FY 2013. http://grants.nih.gov/grants/guide/notice-files/NOT-OD-13-064.html. Accessed 06 Oct 2013
5. Haber JS, Banu MA, Ray A, Kesavabhotla K, Boockvar JA (2013) Industry progress report on neuro-oncology: a biotech update. J Neurooncol 112:315-321. doi: 10.1007/s11060-012-1036-8
6. Phuphanich S, Wheeler CJ, Rudnick JD, Mazer M, Wang H, Nuno MA, Richardson JE, Fan X, Ji J, Chu RM, Bender JG, Hawkins ES, Patil CG, Black KL, Yu JS (2013) Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma. Cancer immunol immunother 62:125-135. doi: 10.1007/s00262-012-1319-0
7. Saikali S, Avril T, Collet B, Hamlat A, Bansard JY, Drenou B, Guegan Y, Quillien V (2007) Expression of nine tumour antigens in a series of human glioblastoma multiforme: interest of EGFRvIII, IL-13Ralpha2, gp100 and TRP-2 for immunotherapy. J Neurooncol 81:139-148. doi: 10.1007/s11060-006-9220-3
8. Zhang JG, Eguchi J, Kruse CA, Gomez GG, Fakhrai H, Schroter S, Ma W, Hoa N, Minev B, Delgado C, Wepsic HT, Okada H, Jadus MR (2007) Antigenic profiling of glioma cells to generate allogeneic vaccines or dendritic cell-based therapeutics. Clin Cancer Res 13:566-575. doi: 10.1158/1078-0432.CCR-06-1576
9. Rebetz J, Tian D, Persson A, Widegren B, Salford LG, Englund E, Gisselsson D, Fan X (2008) Glial progenitor-like phenotype in low-grade glioma and enhanced CD133-expression and neuronal lineage differentiation potential in high-grade glioma. PLoS ONE 3:e1936. doi: 10.1371/journal.pone.0001936
10. Prins RM, Wang X, Soto H, Young E, Lisiero DN, Fong B, Everson R, Yong WH, Lai A, Li G, Cloughesy TF, Liau LM (2013) Comparison of glioma-associated antigen peptide-loaded versus autologous tumor lysate-loaded dendritic cell vaccination in malignant glioma patients. J Immunother 36:152-157. doi: 10.1097/CJI.0b013e3182811ae4
11. Wheeler CJ, Black KL (2009) DCVax-Brain and DC vaccines in the treatment of GBM. Expert Opin Investig Drugs 18:509-519. doi: 10.1517/13543780902841951
12. See AP, Pradilla G, Yang I, Han S, Parsa AT, Lim M (2011) Heat shock protein-peptide complex in the treatment of glioblastoma. Expert Rev Vaccines 10:721-731. doi: 10.1586/erv.11.49
13. Binder RJ, Han DK, Srivastava PK (2000) CD91: a receptor for heat shock protein gp96. Nat Immunol 1:151-155. doi: 10.1038/77835
14. Binder RJ, Srivastava PK (2004) Essential role of CD91 in re-presentation of gp96-chaperoned peptides. Proc Natl Acad Sci USA 101:6128-6133. doi: 10.1073/pnas.0308180101
15. Yang I, Fang S, Parsa AT (2010) Heat shock proteins in glioblastomas. Neurosurg Clin N Am 21:111-123. doi: 10.1016/j.nec.2009.09.002
16. Crane CA, Han SJ, Ahn B, Oehlke J, Kivett V, Fedoroff A, Butowski N, Chang SM, Clarke J, Berger MS, McDermott MW, Prados MD, Parsa AT (2013) Individual patient-specific immunity against high-grade glioma after vaccination with autologous tumor derived peptides bound to the 96 KD chaperone protein. Clin Cancer Res 19:205-214. doi: 10.1158/1078-0432.CCR-11-3358
17. Francisco JA, Cerveny CG, Meyer DL, Mixan BJ, Klussman K, Chace DF, Rejniak SX, Gordon KA, DeBlanc R, Toki BE, Law CL, Doronina SO, Siegall CB, Senter PD, Wahl AF (2003) cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 102:1458-1465. doi: 10.1182/blood-2003-01-0039
18. Vaklavas C, Forero-Torres A (2012) Safety and efficacy of brentuximab vedotin in patients with Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Ther Adv Hematol 3:209-225. doi: 10.1177/2040620712443076
19. Feng H, Hu B, Vuori K, Sarkaria JN, Furnari FB, Cavenee WK, Cheng SY (2013) EGFRvIII stimulates glioma growth and invasion through PKA-dependent serine phosphorylation of Dock180. Oncogene. doi: 10.1038/onc.2013.198
20. Estrada-Bernal A, Lawler SE, Nowicki MO, Chaudhury AR, Van Brocklyn JR (2011) The role of sphingosine kinase-1 in EGFRvIII-regulated growth and survival of glioblastoma cells. J Neurooncol 102:353-366. doi: 10.1007/s11060-010-0345-z
21. Skog J, Wurdinger T, van Rijn S, Meijer DH, Gainche L, Sena-Esteves M, Curry WT Jr, Carter BS, Krichevsky AM, Breakefield XO (2008) Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol 10:1470-1476. doi: 10.1038/ncb1800
22. Al-Nedawi K, Meehan B, Rak J (2009) Microvesicles: messengers and mediators of tumor progression. Cell Cycle 8:2014-2018
23. Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, Reulen HJ, ALA-Glioma Study Group (2006) Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 7:392-401. doi: 10.1016/S1470-2045(06)70665-9
24. McGirt MJ, Chaichana KL, Gathinji M, Attenello FJ, Than K, Olivi A, Weingart JD, Brem H, Quinones-Hinojosa AR (2009) Independent association of extent of resection with survival in patients with malignant brain astrocytoma. J Neurosurg 110:156-162. doi: 10.3171/2008.4.17536
25. Chen L, Mu Z, Hachem P, Ma CM, Wallentine A, Pollack A (2010) MR-guided focused ultrasound: enhancement of intratumoral uptake of [(3)H]-docetaxel in vivo. Phys Med Biol 55:7399-7410. doi: 10.1088/0031-9155/55/24/001
26. Chen X, Cvetkovic D, Ma CM, Chen L (2012) Quantitative study of focused ultrasound enhanced doxorubicin delivery to prostate tumor in vivo with MRI guidance. Med Phys 39:2780-2786. doi: 10.1118/1.4705346
27. Cohen ZR, Zaubermann J, Harnof S, Mardor Y, Nass D, Zadicario E, Hananel A, Castel D, Faibel M, Ram Z (2007) Magnetic resonance imaging-guided focused ultrasound for thermal ablation in the brain: a feasibility study in a swine model. Neurosurgery 60:593-600; discussion 600. doi: 10.1227/01.NEU.0000245606. 99946.C6
28. Desai SB, Patil AA, Nikam R, Desai AS, Bachhav V (2012) Magnetic resonance-guided focused ultrasound treatment for uterine fibroids: first study in Indian women. J Clin Imaging Sci 2:74. doi: 10.4103/2156-7514.104307
29. Dobrotwir A, Pun E (2012) Clinical 24 month experience of the first MRgFUS unit for treatment of uterine fibroids in Australia. J Med Imaging Radiat Oncol 56:409-416. doi: 10.1111/j.1754-9485.2012.02376.x
30. Funaki K, Fukunishi H, Sawada K (2009) Clinical outcomes of magnetic resonance-guided focused ultrasound surgery for uterine myomas: 24-month follow-up. Ultrasound Obstet Gynecol 34:584-589. doi: 10.1002/uog.7455
31. Marret H, Bleuzen A, Guerin A, Lauvin-Gaillard MA, Herbreteau D, Patat F, Tranquart F (2011) French first results using magnetic resonance-guided focused ultrasound for myoma treatment. Gynecol Obstet Fertil 39:12-20. doi: 10.1016/j.gyobfe.2010.08.038
32. Monteith SJ, Medel R, Kassell NF, Wintermark M, Eames M, Snell J, Zadicario E, Grinfeld J, Sheehan JP, Elias WJ (2013) Transcranial magnetic resonance-guided focused ultrasound surgery for trigeminal neuralgia: a cadaveric and laboratory feasibility study. J Neurosurg 118:319-328. doi: 10.3171/2012.10.JNS12186
33. Trumm CG, Stahl R, Clevert DA, Herzog P, Mindjuk I, Kornprobst S, Schwarz C, Hoffmann RT, Reiser MF, Matzko M (2013) Magnetic resonance imaging-guided focused ultrasound treatment of symptomatic uterine fibroids: impact of technology advancement on ablation volumes in 115 patients. Invest Radiol 48:359-365. doi: 10.1097/RLI.0b013e3182806904
34. Zippel DB, Papa MZ (2005) The use of MR imaging guided focused ultrasound in breast cancer patients; a preliminary phase one study and review. Breast cancer 12:32-38
35. Larson PS, Starr PA, Bates G, Tansey L, Richardson RM, Martin AJ (2012) An optimized system for interventional magnetic resonance imaging-guided stereotactic surgery: preliminary evaluation of targeting accuracy. Neurosurgery 70:95-103; discussion 103. doi: 10.1227/NEU.0b013e31822f4a91
36. Perez OD, Logg CR, Hiraoka K, Diago O, Burnett R, Inagaki A, Jolson D, Amundson K, Buckley T, Lohse D, Lin A, Burrascano C, Ibanez C, Kasahara N, Gruber HE, Jolly DJ (2012) Design and selection of Toca 511 for clinical use: modified retroviral replicating vector with improved stability and gene expression. Mol Ther 20:1689-1698. doi: 10.1038/mt.2012.83
37. Popov M, Linder C, Deckelbaum RJ, Grinberg S, Hansen IH, Shaubi E, Waner T, Heldman E (2010) Cationic vesicles from novel bolaamphiphilic compounds. J Liposome Res 20:147-159. doi: 10.3109/08982100903218900
38. Dakwar GR, Abu Hammad I, Popov M, Linder C, Grinberg S, Heldman E, Stepensky D (2012) Delivery of proteins to the brain by bolaamphiphilic nano-sized vesicles. J Control Release 160:315-321. doi: 10.1016/j.jconrel.2011. 12.042
39. Kertesz N, Krasnoperov V, Reddy R, Leshanski L, Kumar SR, Zozulya S, Gill PS (2006) The soluble extracellular domain of EphB4 (sEphB4) antagonizes EphB4-EphrinB2 interaction, modulates angiogenesis, and inhibits tumor growth. Blood 107:2330-2338. doi: 10.1182/blood-2005-04-1655
40. Krasnoperov V, Kumar SR, Ley E, Li X, Scehnet J, Liu R, Zozulya S, Gill PS (2010) Novel EphB4 monoclonal antibodies modulate angiogenesis and inhibit tumor growth. Am J Pathol 176:2029-2038. doi: 10.2353/ajpath.2010.090755